


L-838417

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-W009009 | | |
| CAS No.: | 286456-42-6 | | |
| Molecular Formula: | C ₁₉ H ₁₉ F ₂ N ₇ O | | |
| Molecular Weight: | 399.41 | | |
| Target: | GABA Receptor | | |
| Pathway: | Membrane Transporter/Ion Channel; Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|---|----------------------|-------------|-------------|-------------|--------------|
| In Vitro | DMSO : 25 mg/mL (62.59 mM; Need ultrasonic) | | | | | |
| | Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | 10 mg |
| | | Concentration | | | | |
| | | 1 mM | | 2.5037 mL | 12.5185 mL | 25.0369 mL |
| | | 5 mM | | 0.5007 mL | 2.5037 mL | 5.0074 mL |
| 10 mM | | 0.2504 mL | 1.2518 mL | 2.5037 mL | | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (5.01 mM); Clear solution | | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | L-838417 is a selective partial agonist at the α ₂ , α ₃ and α ₅ subtypes of the GABA _A receptor and an antagonist at the α ₁ , with binding K _i values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α ₁ β ₃ γ ₂ , α ₂ β ₃ γ ₂ , α ₃ β ₃ γ ₂ , α ₄ β ₃ γ ₂ , α ₅ β ₃ γ ₂ and α ₆ β ₃ γ ₂ ^[1] . |
| IC₅₀ & Target | Ki: 0.79 nM (α ₁ β ₃ γ ₂), 0.67 nM (α ₂ β ₃ γ ₂), 1.67 nM (α ₃ β ₃ γ ₂), 267 nM (α ₄ β ₃ γ ₂), 2.25 nM (α ₅ β ₃ γ ₂) and 2183 nM (α ₆ β ₃ γ ₂) ^[1] . |
| In Vivo | L-838417 (1.0 mg/kg) produces anxiolytic effects in adult rat, as indexed by a transformation of social avoidance into preference and an increase in social investigation ^[2] . L-838417 (2.0 mg/kg) eliminates social avoidance, but has no anxiolytic effects on social investigation ^[2] . L-838417 (0.5 mg/kg) reverses the anxiogenic effects of prior stress regardless of age, but with doses ≥ 1 mg/kg decreases social investigation, an effect possibly due in part to locomotor-impairing effects of this compound ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|-----------------|---|
| Animal Model: | Male and female adolescent and adult Sprague–Dawley rats ^[2] . |
| Dosage: | 0, 0.5, 1.0, 2.0, or 4.0 mg/kg. |
| Administration: | IP. |
| Result: | Adolescents required a higher dose (2 mg/kg) to attenuate their social avoidance. The lowest dose of 0.5 mg/kg was sufficient to reverse the anxiogenic effects of repeated restraint as reflected by a significant increase in the coefficient relative to vehicle-treated animals. |

REFERENCES

- [1]. Ciara McCabe, et al. Subtype-selective GABAergic drugs facilitate extinction of mouse operant behavior. *Neuropharmacology*. 2004 Feb;46(2):171-8.
- [2]. Melissa Morales, et al. Anxiolytic effects of the GABAA receptor partial agonist, L-838,417: Impact of age, test context familiarity, and stress. *Pharmacol Biochem Behav*. 2013 Aug;109:31-7.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA